Sutro Biopharma, Inc.: updates and filings

STRONASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$9.82

November 13, 2026Market cap $163M

DCF calculator

What Ploutos Investor adds for Sutro Biopharma

Part of Ploutos Investor, €9.99 a month

See the plans

The full history: 10 fiscal years, from 2016
The estimated fair value, with its range and its certainty
The full analysis, 18 a month
More questions to the chat on its filings
Excel with every year
An email when it reports, changes its dividend or an officer buys

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 89 daysAround Feb 12, 2027 · for Q4 2026

last Nov 12, 2026next Feb 12, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

November 2026

August 2026

June 2026

8MonShareholdersShareholder voteDocument

May 2026

March 2026

February 2026

10TueDealMaterial agreement entered, Regulation FD disclosureDocument

December 2025

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 23, 2026 latest annualNov 12, 2026 latest quarterly

Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026
Form10-Q
Nov 12, 2026Results of operations
Form8-K
Nov 9, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
Aug 14, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Aug 14, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Aug 12, 2026Quarterly reportfor the period to Jun 30, 2026
Form10-Q
Aug 12, 2026Results of operations, Regulation FD disclosure
Form8-K
Jul 30, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
Jun 8, 2026Shareholder vote
Form8-K
May 15, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
May 15, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
May 14, 2026Quarterly reportfor the period to Mar 31, 2026
Form10-Q
May 14, 2026Results of operations
Form8-K
May 14, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
May 1, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
Apr 22, 2026Annual report to shareholdersfor the period to Dec 31, 2025
FormARS
Apr 22, 2026Additional annual meeting material
FormDEFA14A
Apr 22, 2026Annual meeting proxy statement
FormDEF 14A
Apr 21, 2026Over-5% holder statement (passive) (amendment)
FormSCHEDULE 13G/A
Apr 21, 2026Over-5% holder statement (passive)
FormSCHEDULE 13G
Apr 1, 2026Filing
FormEFFECT
Mar 30, 2026Correspondence with the SEC
FormCORRESP
Mar 27, 2026Letter from the SEC
FormUPLOAD
Mar 23, 2026Shelf registration for future offerings
FormS-3
Mar 23, 2026Shares registered for employees
FormS-8

Filed	Form	What it is	Filing
Nov 12, 2026	10-Q	Quarterly reportfor the period to Sep 30, 2026	Document
Nov 12, 2026	8-K	Results of operations	Document
Nov 9, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
Aug 14, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Aug 14, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Aug 12, 2026	10-Q	Quarterly reportfor the period to Jun 30, 2026	Document
Aug 12, 2026	8-K	Results of operations, Regulation FD disclosure	Document
Jul 30, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
Jun 8, 2026	8-K	Shareholder vote	Document
May 15, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
May 15, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
May 14, 2026	10-Q	Quarterly reportfor the period to Mar 31, 2026	Document
May 14, 2026	8-K	Results of operations	Document
May 14, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
May 1, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
Apr 22, 2026	ARS	Annual report to shareholdersfor the period to Dec 31, 2025	Document
Apr 22, 2026	DEFA14A	Additional annual meeting material	Document
Apr 22, 2026	DEF 14A	Annual meeting proxy statement	Document
Apr 21, 2026	SCHEDULE 13G/A	Over-5% holder statement (passive) (amendment)	Document
Apr 21, 2026	SCHEDULE 13G	Over-5% holder statement (passive)	Document
Apr 1, 2026	EFFECT	Filing	Document
Mar 30, 2026	CORRESP	Correspondence with the SEC	Document
Mar 27, 2026	UPLOAD	Letter from the SEC	Document
Mar 23, 2026	S-3	Shelf registration for future offerings	Document
Mar 23, 2026	S-8	Shares registered for employees	Document

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 8, 2006.

And 338 filings on insiders' shares300 Form 4, 3 Form 144 and 35 Form 3 since Sep 26, 2018. Their trades are on the Ownership tab.

The full analysis

What do Sutro Biopharma's filings show?

The filings are where every one of Sutro Biopharma's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

A fair value range built from the filings
Earnings quality, debt and red flags
Insider and institutional moves
The case for and the case against

All filings on EDGAR

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.